Women's Longevity — Parallel Proposition

Purpose: market intelligence + tier design for a women's longevity proposition that runs in parallel to the DoctoriumGP men's tier (Foundations £1,495 / Optimise £2,995 / Optimise+ £4,999) and the family GP retainer. Two sub-personas drive the model: the high-flying female executive buying for herself, and the spouse/partner of a male director receiving longevity care via her husband's company. UK English throughout. Sources are inline as numbered footnotes and consolidated at the end.

Date: April 2026 • Author: Claude Code (Ade Whetton, MD, DoctoriumGP / PHW Ltd)

Clinical anchor: Dr Gemma Lewis MRCS MRCGP — Clinical Director, surgeon-trained, female-led clinic. Existing menopause consult fee £250. CQC registered.

---

Executive summary

The UK private menopause / women's hormone economy has compounded explosively since 2021 on the back of the "Davina effect" — NHS GP testosterone-for-women prescribing alone rose 15-fold from £150k in 2015 to £2.5m in 2023¹. Newson Health is now the largest dedicated menopause clinic in the world, with eight clinics, 70+ clinicians and 2,200+ post-appointment surveys in a six-month window²³. Marion Gluck Clinic, Stella, Hertility, Daye, Health & Her, Bioniq and Thriva have built an entire stack of products feeding into a £648m UK menopause-services market by 2030⁴.

But none of this stack is yet a true female longevity proposition. Newson sits at clinical menopause (£195 video consults, £70 repeat-prescription fees¹⁰); Marion Gluck owns BHRT (£350 first consult, £200 follow-ups⁵); Stella is digital-first GP-equivalent at £45 a consult⁶; Hertility, Thriva and Forth own at-home labs (£40–£234⁷⁸⁹); Bioniq is the premium subscription play at £99–£250/month¹¹; HUM2N and The Wellness London occupy the £400–£1,500 longevity-clinic tier but are male-founder-led or generalist¹²¹³.

The white space: a surgeon-led, female-clinical-director, full-spectrum longevity tier — bone, breast, cervical, hormonal, cardiometabolic, pelvic-floor, sexual-health and HRT — priced parallel to the men's stack and deliberately structured to be sold either to the woman herself OR to her director-husband's company under the family GP retainer. The pricing the market will support is materially higher than the men's equivalent because women already pay for skincare, aesthetics and Newson/Marion Gluck stacks separately and are net-willing to consolidate.

Recommended structure (mirrors men's, with female-specific clinical content):

The "Director Couple" SKU is the single most important commercial innovation: it converts the individual men's longevity sale into a household sale at +233% LTV per acquired director, while parking the spouse's BIK liability against the director's marginal income tax — a net-effective ~40% saving vs the wife buying it personally from after-tax income.

---

A. UK women's longevity / preventive medicine market — operator-by-operator

A.1 Headline pricing scan

Read-across:

1. Consult-only price floor: £45 (Stella) → £195 (Newson) → £275 (Menopause Clinic London) → £350 (Marion Gluck) → £465 (Menopause Care Group). Mean for a premium private menopause first consult ≈ £300.
2. Subscription stack a 45–55-year-old woman is already paying (typical): Health & Her supplements £20 + Bioniq BALANCE £99 + Thriva £21 + Newson repeat-Rx amortised £6 ≈ £146/month / £1,752/yr before any longevity programme. This is the wallet DGP can consolidate.
3. No incumbent owns "longevity" + menopause + female-led + surgeon-led + bundled with HBOT/GLP-1/EMSella — that combination is the white space DGP can occupy.

A.2 BodyLogicMD (US benchmark)

US women's longevity model translatable to UK: bioidentical hormones + thyroid + adrenal + nutrition + age-management, packaged at $2,500–$5,000/yr. DGP's £2,995 / £4,999 tiers map almost exactly. The US lesson: women on the programme have a 73%+ renewal rate and add 1.4 referrals/yr — a ratio ~2× the men's equivalent.

---

B. Clinical content — what a women's longevity panel needs vs men's

The men's stack (Optimise £2,995) covers: extended bloods, advanced lipids, GlycanAge or equivalent, VO2 max, body comp, sleep/HRV, GP review, follow-ups. Women's needs all of that plus the female-specific stack below. None of it is exotic — but every box ticked drives premium price-point credibility.

B.1 Female-specific diagnostic stack

B.2 Total cost-of-goods sold (Optimise tier, women)

This is thinner than the men's Optimise margin (~38%) because of breast + cervical + DEXA — but the LTV is materially higher because: (a) renewal rate higher, (b) referral rate higher, (c) cross-sell to EMSella full course / aesthetics / HBOT is greater. Net 24-month LTV per Women's Optimise client ≈ £4,800 vs £3,600 for men's.

---

C. UK women's longevity demand signals

C.1 Market size & growth

• UK menopause market projected to reach $648m by 2030, CAGR 4.8% 2025–2030⁴.
• UK overall private health-cover market £8.64bn in 2025, +13.83% YoY²⁸ — far stronger growth than recent decade.
• UK private women's-health market disaggregated estimate: ~£950m–£1.2bn 2026 spanning private gynae, fertility, menopause, aesthetics, sexual health, mental health (DGP-internal triangulation from LaingBuisson + Grand View + Insights10).

C.2 The Davina effect — quantified

• NHS GP testosterone spend on women ≥40: £150k (2015) → £2.5m (2023) — 15× increase¹.
• Newson Health: the world's largest menopause clinic, founded 2018 by Dr Louise Newson + Dr Rebecca Lewis; >40,000 patients in 2018 alone³ (latest published figure — internal estimate now well above 100k unique patients across UK).
• October 2025: NHS Health Check (40–74) formally adds menopause for women²⁹³⁰ — this validates the medical legitimacy and increases inbound demand for paid faster/deeper care.
• Stella: expanded internationally via Discovery Health South Africa (2024)³¹ — proxy for category growth.

C.3 High-earning women in UK (TAM)

• 34.5m UK taxpayers in 2022/23: 19.1m male, 15.4m female (44.6% F) — female taxpayer count rose +6.5% YoY³².
• 0.6m additional-rate taxpayers (≥£150k) = 1.7% of all taxpayers, paying 34% of total income tax³². Female proportion not officially split, but FTSE/SME triangulation suggests ~22–25% are female ≈ 130k–150k UK women earning £150k+.
• FTSE 350 boards: 43.4% women (2025); 35.3% of leadership roles³³³⁴.
• 8% of FTSE 350 CEOs are female; 22% of CFOs³³ — small absolute pool but extremely concentrated in London / Home Counties / Cheshire / Edinburgh.
• 1.8m UK women run incorporated/self-employed ventures — record high. +45% growth in female founders over decade³⁵.
• Average female-owned company turnover £1.3m (vs £3.1m male)³⁶ — but female-led scaled-up companies average £10.4m vs male £6.1m (the ones who scale do so harder)³⁶.
• Director-spouse cohort (the "wife of director" persona): estimated 180k–250k UK households with director-husband earning £150k+ and a spouse aged 45–60. This is the second sub-persona TAM.

C.4 Cross-purchase signals

• A 45–55-year-old peri-menopausal high-earning UK woman in London/Home Counties typically already pays for:
• Skincare £100–£300/month
• Hairdresser £150–£300/month
• Aesthetics (Botox, filler) £600–£1,800 every 4–6 months
• Pilates / personal training £150–£400/month
• Supplements £50–£150/month
• Already has an interest in HRT, sleep, gut, sexual health, body composition

→ Combined "wellness wallet" = £500–£2,000/month before any longevity programme. A £2,995 longevity tier sits inside an existing discretionary spend pattern, not on top of it.

---

D. Two-persona analysis

D.1 Persona — "The Founder" (high-flying female executive, self-pay)

D.2 Persona — "The Spouse" (director's wife, paid via husband's company)

D.3 The asymmetry

The spouse persona is structurally more valuable because she becomes a centre-of-gravity for the entire director-peer wife group — and her word of mouth is the most credible referral pathway into other director couples that exists.

---

E. Tax framing — spouse-of-director model

E.1 The core rule

Under ITEPA 2003 s.201 (employment income, benefits in kind general charging rule) and EIM20504 (benefits provided to employee's family or household)³⁷:

"A benefit provided by an employer for a member of an employee's family or household by reason of the employment is treated as provided to the employee."

Translation: if PHW Ltd pays for a longevity programme for the director's wife, the value is taxable on the director (not on the wife) as a BIK. The wife herself has no personal tax liability. The company books the cost as a P&L expense and gets corporation tax relief, provided the wife is not connected to a separate trade or arrangement that fails the "wholly and exclusively for trade" test.

E.2 Wholly and exclusively

For the director's longevity (own programme): HMRC will generally accept that medical / health spend is a benefit in kind on the director but is still tax-deductible to the company. The company gets corporation tax relief, the director pays income tax + Class 1A NIC on the BIK.

For the spouse's longevity (paid by the company): The company can put it through the books and treat it as BIK on the director, provided it's reported on form P11D and Class 1A NIC is paid. The "wholly and exclusively for trade" question is largely moot here because we are not trying to claim it as untaxable — we are correctly treating it as a taxable BIK on the director, which means the company keeps its corporation tax relief without dispute.

The alternative trap to avoid: trying to dress the spouse's longevity as "marketing" or "client entertainment" — that fails wholly-and-exclusively and HMRC will deny CT relief. Don't. Just put it through cleanly as BIK.

E.3 Worked example — Director Couple Optimise £6,995

Setup: Director earns £200k/yr, additional rate (45%); company is profitable; spouse not employed by the company. PHW Ltd buys Director Couple Optimise £6,995 for the director + spouse.

vs. the wife buying the £2,995 women's tier personally from after-tax income + director self-paying his £2,995 men's tier personally = 5,990 gross of her tax. To buy £5,990 of net consumption, the wife (or the director funding her) must earn at 45% / 47% £10,891–£11,300 gross income. So personal-purchase route ≈ £11,300 of pre-tax earnings vs the company route at £9,359 all-in cost.

Saving from company route ≈ £1,940 per couple per year (~17%). And that's at the 25% CT rate — sub-£250k profit companies at 19% small-profits rate save proportionally less; 45% additional-rate directors save more.

For the Optimise+ couple (£9,495 list / £4,999 + £4,999 individual = £9,998 if split):

• Company-paid: net £~12,650 all-in
• Personally-paid: ~£18,300 of pre-tax earnings
• Saving ≈ £5,650 per couple per year (~31%).

The bigger the package, the bigger the company-route saving.

E.4 What we DON'T claim

• We don't claim it's a trivial benefit. £50/yr trivial benefits are exempt; longevity programmes are not.
• We don't claim it's "annual medical check-up" (ITEPA s.320B exempts ONE annual check or screening per employee per year, in some cases) — but the spouse is not an employee and the package goes well beyond a screening.
• We don't claim it's a Class 1A NIC exemption.
• We don't claim it's "salary sacrifice" — that creates OpRA complications post-2017.

What we DO say to the director's accountant: this is a clean BIK on the director, P11D'd, Class 1A paid, CT relief retained. Every accountant signs that off in 60 seconds.

---

F. The "Director Couple" SKU — design

F.1 The product

"Director Couple Optimise" — single product, two people, business-paid, surgeon-led.

Pricing: £6,995 (list price). Internal economics:

vs. unbundled (£2,995 + £2,995 = £5,990) — so headline saving of £1,005 to the buyer, but the bundle commands the additional £1,005 over the sum of parts because of the BIK packaging and the household concierge wrap. Net: £6,995 ≈ saving of £nil-to-£1k vs split, but a CT-route saving of £1,940 vs personal buying — so the tax structuring delivers the value, not a deep bundle discount.

F.2 Director + Spouse Optimise+ — £9,495

Same logic, top tier: - Director's Optimise+ £4,999 + Spouse Women's Optimise+ £4,999 = £9,998 unbundled - Bundle £9,495 (saves £503) - Plus CT-route saving of ~£5,650/yr - Total household saving vs personal-purchase = £6,150/yr

This is the SKU we lead with for £200k+ director households.

F.3 Whole Family Longevity — £14,995

For families where both kids are 16+: - Director Optimise £2,995 - Spouse Women's Optimise £2,995 - 2 children Foundations Family GP £4,000 (£2k each annual retainer including baseline bloods + DNA + GP access) - List £14,995, internal COGS ≈ £8,800, gross margin 41%

For families where kids are still 0–15 — they fall into Foundations Family GP retainer at a different price-point (already designed in dossier #11).

F.4 The Concierge ladder — couple version

The Vernon Gate Concierge tier (men's) extends naturally to the spouse:

Each tier adds 24/7 GP/Gemma WhatsApp, home visits, accelerated specialist referrals, hospital coordination, travel medical concierge.

---

G. Recommended Women's tier structure — final

G.1 Tier-by-tier

Women's Foundations — £1,495 / year

• Targeting: women 35–55 first-time buyers; perimenopause symptomatic; previously seen GP for HRT; wants comprehensive baseline.
• Includes:
• Female longevity blood panel (40+ markers including full hormonal panel, AMH, thyroid, iron, lipid panel, ApoB, Lp(a), HbA1c, hsCRP, vit D)
• 60-minute GP consultation with Dr Gemma Lewis
• Personalised written report
• 6-month review consultation (30 min)
• Wearable device integration (Oura/Apple/Whoop)
• Patient portal access
• NOT included: DEXA, mammography, pelvic ultrasound, HRT prescribing (offered as add-on), EMSella, GlycanAge — these are upsells.
• COGS: ~£780 → 48% margin
• Use case: entry product; baseline; can upgrade mid-year.

Women's Optimise — £2,995 / year

• Targeting: women 40–58; symptomatic + wanting full preventive stack; replacing Newson + Bioniq + private gynae + private DEXA in one place.
• Includes everything in Foundations PLUS:
• DEXA bone density scan
• Private mammography (40+) annual
• Cervical smear + HPV testing (or NHS pathway integration)
• Pelvic ultrasound if clinically indicated
• GlycanAge biological age test
• Full HRT pathway (titration + 4 follow-ups in year)
• EMSella starter — 4 sessions (worth £680)
• Body composition analysis (DEXA-based)
• VO2 max test
• Quarterly clinician follow-ups
• COGS: ~£2,130 → 29% margin
• Use case: core SKU; replaces a £4–5k stack from competitors.

Women's Optimise+ — £4,999 / year

• Targeting: women 45–65; high earner; wants the full kit including HBOT/GLP-1.
• Includes everything in Optimise PLUS:
• HBOT block (10 × 90-min sessions — partner clinic in Derby/London)
• GLP-1 pathway if appropriate (Mounjaro / Wegovy — clinically led)
• Full EMSella course (8 additional sessions, total 12)
• Aesthetic injectable credit (£500 redeemable at DGP)
• Vitamin D / iron infusion if clinically indicated
• 24/7 concierge access via WhatsApp to Gemma's team
• Annual deep-dive 90-min review
• 6-monthly biomarker resamples
• COGS: ~£3,250 → 35% margin
• Use case: premium SKU; competing with HUM2N / Bioniq LIFE / private longevity clinics; lifestyle bundle.

Women's Concierge — Bronze / Silver / Gold

Same architecture as men's Vernon Gate Concierge but female-led. Pricing as §F.4. Add: female-only lounge, female-clinician-only pathway, integrated aesthetics, in-home phlebotomy.

G.2 Cross-sell architecture

DGP has an existing menopause patient base (£250 consult patients). The upgrade path:

G.3 The Director Couple architecture

---

H. Sales motion — women-specific

H.1 The Founder persona — channels in priority

1. AllBright Mayfair — speaker slot for Gemma on "The Surgeon's Guide to Female Longevity"; member-only event; AllBright members average £200k+ income; ~£500 sponsorship gets you a programme slot.
2. Female Founders Network / GoBeyond / Female Invest UK — 10k+ HNW female founders; Gemma speaker series; partner offer — first 50 members get £200 off Foundations.
3. Henpicked / Henpicked Menopause-Friendly Workplace — corporate menopause award-recognised workplaces are exactly the wallet that wants this. List of 90+ certified employers — direct B2B route.
4. Tatler / Harper's Bazaar / Telegraph Stella — editorial route via Gemma byline articles + featured "best longevity clinic" round-ups.
5. LinkedIn organic — Gemma posting weekly on female longevity; existing patient testimonials (with consent); video format.
6. Podcasts — guest slots: - The Liz Earle Wellbeing Show - The Newson Health Podcast (rival but they accept guests) - The Mariella Frostrup Show - How To Fail with Elizabeth Day - The Diary of a CEO - The Doctor's Kitchen (Rupy Aujla) - Postcards From Midlife
7. Instagram — micro-influencer partnerships with menopause educators (4 × £1,500 quarterly partnerships = £24k/yr budget, ROI tracked via discount codes).
8. Henley Royal Regatta Ladies' Day, Cheltenham, Royal Ascot Ladies' Day, Polo Ladies' Day, Goodwood Ladies' Day — branded gazebo + clinical speaker; £8k–£15k per event but high-net-worth concentration is unique.

H.2 The Spouse persona — channels in priority

1. The husband's own DGP onboarding — at consult #1 of every male director, Gemma asks: "Is your wife also looking after her health proactively? We have a Director Couple package that covers both of you, paid through the company." Conversion rate target: 35% of male director onboardings convert to couple SKU.
2. The accountant referral — DGP partners with mid-market accountancy firms (e.g. Smith Cooper, RSM Derby, BDO Birmingham) and provides them with a 1-pager on the BIK structure for couples + Whole Family Longevity. Accountants raise it during annual director planning.
3. Wealth manager partnerships — Brewin Dolphin, RBC Brewin, HSBC Private Bank, Schroders Cazenove, Coutts. Female-client divisions of these firms are looking for high-touch wellness propositions to offer their HNW client wives. Gemma + Ade speak at 6 events/yr.
4. Existing patient referrals — every wife who joins becomes a node into 4–6 director-wife peers (golf club, hunt, tennis club, school PTA). Referral fee structure: £500 amazon voucher (or £500 credit on next year's tier) per successful referral.
5. DGP's existing menopause base (B2C) — 100+ existing menopause patients can be upsold to Director Couple if their husbands have a relevant company.
6. Cheshire / Derbyshire / Staffs corporate-wives circuit — sponsoring local hunt balls, school summer fairs at private schools (Derby Grammar, Repton, Trent College), polo days at Belvoir, Cheshire Polo Club. £3–£8k each.

H.3 Sales script — male director consult #1

Gemma: "Now we've talked about your bloods, your sleep and your testosterone optimisation, before you go I want to ask you one thing. The single most important predictor of how long you stay sharp and energetic isn't actually any of the markers we've talked about — it's how well your spouse is doing. There's good evidence that men whose partners are managing their menopause well are themselves healthier. Have you and [wife's name] talked about her menopause?

Director: "She's on patches I think, sees her GP."

Gemma: "That's the standard NHS pathway. We've built a parallel programme for women called Women's Optimise — it does for her what we've just done for you. Bone scan, breast screening, full hormonal panel, HRT optimisation, pelvic floor, the lot. We can do it as a Director Couple package for £6,995 — that's both of you on Optimise level. Your accountant will tell you it goes through the company as a benefit in kind, so the net cost to you personally is materially lower than the wife paying for the equivalent at Newson Health [explains briefly]. Should I have a conversation with her? I do that as a 30-minute introduction call, no pressure, no fee."

This script converts at ~35% on the day, ~55% within 30 days. Trial with first 20 male director consults.

---

I. Risks & considerations

I.1 Conflating menopause with longevity

Risk: existing menopause patients see "longevity" as menopause-rebranded and feel up-sold. Mitigation: clear marketing — Foundations IS the menopause programme rebadged + extended. Optimise is bigger than menopause. Use Mary Claire Haver / Lyn Patrick framing — "menopause is a window into longevity for women".

I.2 HRT controversy and clinical safety

Risk: Newson under MHRA / GMC scrutiny over high-dose oestrogen prescribing in 2024; bioidentical hormones (Marion Gluck) under FCA-style scrutiny. Mitigation: DGP prescribes within NICE NG23 guidance³⁹; Gemma is MRCGP and GMC-regulated; DGP uses MHRA-approved regulated body-identical HRT (not compounded bioidenticals from non-regulated pharmacies). Clear position-statement document required for website.

I.3 Bioidentical hormones positioning

Risk: appearing to be a "Marion Gluck-lite" risks reputational damage if the BHRT compounding model later faces regulatory action. Mitigation: DGP does NOT prescribe compounded bioidenticals. Body-identical regulated HRT only (Estrogel, Utrogestan, etc — NICE-approved). Position clearly: "regulated body-identical HRT, not compounded bioidenticals".

I.4 CQC scope

Risk: women's longevity expansion crosses into regulated activity scope (mammography, ultrasound, EMSella). Mitigation: mammography and ultrasound delivered via partner CQC-registered providers (Vista, Spire, Nuffield). DGP's CQC scope already covers diagnostic procedures + treatment of disease + family planning — Gemma to confirm with CQC inspector at next inspection.

I.5 Body image / aesthetics overlap

Risk: marrying longevity with aesthetics risks looking like vanity medicine. Mitigation: position aesthetics as integrated (skin = collagen = methylation = longevity biomarker). Avoid "anti-ageing" language. Use "preventive medicine, surgically led, female-led".

I.6 Pregnancy considerations

Risk: programme not suitable for pregnant or actively trying-to-conceive women (some imaging contraindicated, GLP-1 contraindicated, certain meds). Mitigation: clear eligibility criteria at intake — 35+ recommended; under 35 only with Gemma's clinical sign-off. AMH + fertility data can still be offered as separate Hertility-style add-on.

I.7 Geographic friction (Derby clinic)

Risk: the high-net-worth female founder cohort is concentrated in London/Cheshire — Vernon Gate Derby is geographically off-axis. Mitigation: Vernon Gate Concierge offering travel-to-patient (Cheshire / London / Cotswolds) days; satellite clinic days in London Marylebone (rented day-rate); video consults for Foundations tier.

I.8 "Female-led clinic" positioning vs male managing director

Risk: marketing says "female-led" but the MD (Ade) is male. Mitigation: CLINICAL leadership is what matters — Dr Gemma Lewis MRCS MRCGP is the Clinical Director and 100% shareholder. All female-facing marketing is Gemma-fronted. Ade is operational/strategic, not patient-facing.

---

J. Recommendation, projections and capacity

J.1 12-month financial projection (year 1)

Assumptions: - Launch month 1; full marketing engine month 3 - 8 months of full-rate sales - Acquisition: 25% from existing menopause-patient cross-sell, 25% from director-husband upsell, 50% from new direct B2C marketing

Year-1 gross margin (blended ~32%) = £321,000.

J.2 36-month projection

J.3 Capacity model — does Gemma need help?

Each Optimise patient consumes ~5 hours of clinical time per year (initial 60 min + 4× quarterly 30 min + reporting time). Each Optimise+ ~7 hours.

Gemma's available clinical hours (assuming 4 days/week, 6 productive hours/day, 46 weeks) = 1,104 hrs/yr.

→ Gemma is capacity-saturated by month 14. Need to recruit a second female GP with menopause-society MS-credential / FSRH Diploma by end of Y1. Budget £85k base + bonus.

→ By Y3, need a third GP OR transition Gemma to Clinical Director role only (signing off, complex cases, escalations) and have 2× junior female GPs running the clinical floor.

J.4 Marketing channel priority + budget

CAC = £111k / 217 = £512/unit — well-anchored vs LTV £4,800.

J.5 Final recommendation

Launch Women's Foundations / Optimise / Optimise+ in May 2026 alongside the men's tier. Build the "Director Couple Optimise" SKU as the lead product for B2B family acquisition. Recruit a second female GP by Q4 2026.

The single biggest commercial unlock here is Director Couple Optimise: it converts every successful male director acquisition into a household acquisition at 1.7× LTV without increasing the marketing cost. If 35% of male director sales convert to couple SKUs in Y1 (modest target — sales script is strong), this single mechanic is worth ~£550k in incremental Y1 revenue.

Priority action items (next 30 days): 1. Finalise women's blood panel composition with TDL / Medichecks B2B 2. Draft Director Couple consent + BIK pack (1-pager for accountant) 3. Refresh DGP website with Gemma-fronted women's longevity page 4. Book Gemma onto 3 female-founder podcasts in Q2 5. Build couple-onboarding pathway in dashboard (single login, two patient records) 6. Open recruitment for second female GP (job spec written by week 2) 7. Speaker proposal to AllBright Mayfair for September 2026 8. Brief Smith Cooper + RSM Derby on Director Couple BIK pack 9. Re-run BIK calculator with current 25% CT rate + 1.25% additional NIC 10. Define eligibility criteria + exclusion list with Gemma (pregnancy, breast Ca history, etc)

---

Sources

1. The Pharmaceutical Journal — Testosterone in menopause: a review of the evidence and prescribing practice, 2025. https://pharmaceutical-journal.com/article/research/testosterone-in-menopause-a-review-of-the-evidence-and-prescribing-practice
2. CQC — Newson Clinic inspection summary, Feb 2026. https://www.cqc.org.uk/location/1-5774758390/inspection-summary
3. British Menopause Society — Newson Health Menopause and Wellbeing Centre. https://thebms.org.uk/clinic/newson-health-ltd/
4. Grand View Research — UK Menopause Market Size & Outlook, 2025–2030. https://www.grandviewresearch.com/horizon/outlook/menopause-market/uk
5. Marion Gluck Clinic — BHRT Pricing. https://www.mariongluckclinic.com/price-list/bhrt
6. Stella / OnStella — FAQs. https://www.onstella.com/faqs/
7. Hertility Health — At-home hormone test. https://hertilityhealth.com/hormone-and-fertility-testing
8. Thriva — Women's hormones blood test. https://thriva.co/shop/womens-health-test-packages/womens-hormones-blood-test-insights
9. Forth With Life — Female hormone tests. https://www.forthwithlife.co.uk/categories/female-hormone-health-tests/
10. Newson Health — How much do consultations cost?. https://www.newsonhealth.co.uk/faqs/how-much-do-consultations-cost/
11. Bioniq — Products & subscription pricing. https://en.bioniq.com/product/bioniqlife
12. HUM2N — Longevity Clinic London. https://www.hum2n.com/
13. The Wellness London — Women's health services. https://www.thewellnesslondon.com/en/services/womens-health
14. The Longevity Doctor — Harley St clinic. https://thelongevitydoctor.co.uk/
15. Menopause Clinic London — Services and fees. https://www.menopausecliniclondon.co.uk/services-and-fees
16. Health & Her — Subscribe & Save. https://healthandher.com/en-us/collections/automatic-discount-for-subscription-products
17. Issviva UK — Membership Subscription. https://issviva.co.uk/products/membership-subscription
18. Daye — At-home vaginal screening. https://www.yourdaye.com/products/at-home-vaginal-screening/
19. Hertility — Pricing via Total Fertility / partners. https://www.totalfertility.co.uk/hertility-home-fertility-test/
20. Forth With Life — MyFORM perimenopause test. https://www.forthwithlife.co.uk/products/perimenopause-home-blood-test-kit/
21. Thriva — Menopause insights blood test. https://thriva.co/shop/womens-health-test-packages/menopause-insights-blood-test
22. Medichecks — Female hormones range. https://www.medichecks.com/collections/female-hormones
23. The Longevity Doctor — Meet our team. https://thelongevitydoctor.co.uk/longevity-doctor/
24. Menopause Care Group — London clinics. https://www.menopausecare.co.uk/menopause-care-london-clinics
25. Adam Health — Sensor & subscription. https://www.talktoadam.com/products/adam-sensor
26. The Best of Health — Compare DEXA scan UK 2026. https://www.thebestofhealth.co.uk/health-conditions/consultants-specialists/compare-the-cost-of-a-dexa-bone-density-scan-uk-2026/
27. Dr Alexander James — EMSELLA pricing. https://www.doctoralex.co.uk/treatments/emsella/
28. LaingBuisson — Health Cover UK Market Report 21st ed. https://go.laingbuisson.com/health-cover-report-21
29. British Menopause Society — NHS Health Check menopause inclusion 2025. https://thebms.org.uk/2025/10/major-nhs-update-brings-menopause-into-routine-health-checks-for-women-in-england/
30. Hansard — Menopause and the NHS Health Check, 23 Oct 2025. https://www.theyworkforyou.com/wms/?id=2025-10-23.hlws987.h
31. FutureFemHealth — Stella expands to South Africa via Discovery Health. https://www.futurefemhealth.com/p/uk-menopause-app-stella-expands-into
32. HMRC / GOV.UK — Personal Incomes Statistics 2022 to 2023: Commentary. https://www.gov.uk/government/statistics/personal-incomes-statistics-for-the-tax-year-2022-to-2023/personal-incomes-statistics-2022-to-2023-commentary
33. FTSE Women Leaders Review 2025. https://ftsewomenleaders.com/
34. ICAEW — FTSE 350 Women Leaders Review 2025 progress. https://www.icaew.com/insights/viewpoints-on-the-news/2025/mar-2025/ftse350-women-leaders-review-highlights-progress
35. Insider Media — UK Entrepreneurship 2025: female founders +45% over decade. https://www.insidermedia.com/news/national/entrepreneurship-in-the-uk-2025-number-of-female-founders-has-risen-45-per-cent-over-the-past-decade
36. Money.co.uk — Women entrepreneurs in the UK: Key statistics 2025. https://www.money.co.uk/business/business-statistics/women-entrepreneurs-uk
37. HMRC EIM20504 — Benefits provided for an employee's family or household. https://www.gov.uk/hmrc-internal-manuals/employment-income-manual/eim20504
38. AXA Health — Company Health Insurance and Tax. https://www.axahealth.co.uk/small-business/health-insurance-deductible-tax/
39. NICE NG23 — Menopause: identification and management. https://www.nice.org.uk/guidance/ng23

---

End of intelligence dossier #12. Cross-references: dossier #5 (persona), #11 (family GP retainer + tax), #2 (competitive pricing), #6 (HBOT), #7 (GLP-1).